Skip to main content
SpringerLink
Log in

Nebenwirkungen und deren Management

  • Chapter
  • First Online:
Medikamentöse Tumortherapie von Kopf-Hals-Tumoren

  • 374 Accesses

Zusammenfassung

In keinem anderen Gebiet der Medizin gab es in den letzten beiden Jahrzenten mehr Fortschritte als in der medikamentösen Tumortherapie. Mit der Erweiterung der therapeutischen Ansatzpunkte (Zellzyklus/Proliferation, Signaltransduktion, Immunabwehr/Immunsurveillance) hat sich auch der Umfang an potentiellen Nebenwirkungen erheblich erweitert. Das Spektrum der potentiellen Nebenwirkungen von Tumortherapeutika kann prinzipiell alle Organsysteme treffen und reicht von leichtgradigen passageren Symptomen bis hin zu lebensbedrohlichen oder irreversiblen Komplikationen. Alle Nebenwirkungen (unabhängig vom Schweregrad) können die Durchführung und Adhärenz einer Tumortherapie negativ beeinflussen und damit den Therapieerfolg gefährden. Detaillierte Kenntnisse von Nebenwirkungen und deren optimales Management stellen daher einen zentralen Pfeiler der medikamentösen Tumortherapie dar. Das nachfolgende Kapitel gibt daher einen systematischen Überblick über potentielle Nebenwirkungen von Medikamenten, die aktuell in der Behandlung von Kopf-Hals-Tumoren regelmäßig zum Einsatz kommen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Feliu J et al (2020) Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clin Transl Oncol 22(4):457–467

    Article  CAS  Google Scholar 

  2. Oosting SF, Haddad RI (2019) Best practice in systemic therapy for head and neck squamous cell carcinoma. Front Oncol 9:815

    Article  Google Scholar 

  3. Hennequin C, Guillerm S, Quero L (2019) Combination of chemotherapy and radiotherapy: a thirty years evolution. Cancer Radiother 23(6-7):662–665

    Article  CAS  Google Scholar 

  4. Morgan C et al (2011) Management of uncommon chemotherapy-induced emergencies. Lancet Oncol 12(8):806–814

    Article  Google Scholar 

  5. Lotfi-Jam K et al (2008) Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 26(34):5618–5629

    Article  Google Scholar 

  6. Barreto JN et al (2014) Antineoplastic agents and the associated myelosuppressive effects: a review. J Pharm Pract 27(5):440–446

    Article  Google Scholar 

  7. Chan A et al (2012) Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol 81(2):136–150

    Article  Google Scholar 

  8. Crawford J et al (2010) Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol 21(Suppl 5):v248–v251

    Article  Google Scholar 

  9. Repetto L, C. investigators (2009) Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. Crit Rev Oncol Hematol 72(2):170–179

    Article  Google Scholar 

  10. Schmidt-Hieber M et al (2018) Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 97(1):31–49

    Article  CAS  Google Scholar 

  11. Hesketh PJ et al (2017) Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 35(28):3240–3261

    Article  CAS  Google Scholar 

  12. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482–2494

    Article  CAS  Google Scholar 

  13. Navari RM (2016) The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf 15(3):343–356

    Article  CAS  Google Scholar 

  14. Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26(6):1081–1090

    Article  CAS  Google Scholar 

  15. Santos MLC et al (2020) Nephrotoxicity in cancer treatment: an overview. World J Clin Oncol 11(4):190–204

    Article  Google Scholar 

  16. Saftescu S et al (2021) Determining factors of renal dysfunction during cisplatin chemotherapy. Exp Ther Med 21(1):83

    Article  Google Scholar 

  17. Aapro M, Launay-Vacher V (2012) Importance of monitoring renal function in patients with cancer. Cancer Treat Rev 38(3):235–240

    Article  Google Scholar 

  18. Nolin TD, Himmelfarb J (2010) Mechanisms of drug-induced nephrotoxicity. Handb Exp Pharmacol 196:111–130

    Article  CAS  Google Scholar 

  19. Perazella MA, Moeckel GW (2010) Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 30(6):570–581

    Article  CAS  Google Scholar 

  20. Launay-Vacher V et al (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European society of clinical pharmacy special interest group on cancer care. Cancer Chemother Pharmacol 61(6):903–909

    Article  CAS  Google Scholar 

  21. Guo X et al (2020) Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis. Eur J Clin Pharmacol 76(10):1345–1354

    Article  CAS  Google Scholar 

  22. Ramadori G, Cameron S (2010) Effects of systemic chemotherapy on the liver. Ann Hepatol 9(2):133–143

    Article  CAS  Google Scholar 

  23. Chun YS et al (2009) Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 10(3):278–286

    Article  CAS  Google Scholar 

  24. Field KM, Michael M (2008) Part II: liver function in oncology: towards safer chemotherapy use. Lancet Oncol 9(12):1181–1190

    Article  CAS  Google Scholar 

  25. Floyd J et al (2006) Hepatotoxicity of chemotherapy. Semin Oncol 33(1):50–67

    Article  CAS  Google Scholar 

  26. Chan AK, Choo BA, Glaholm J (2011) Pulmonary toxicity with oxaliplatin and capecitabine/5-Fluorouracil chemotherapy: a case report and review of the literature. Onkologie 34(8-9):443–446

    Article  Google Scholar 

  27. Torrisi JM et al (2011) CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 258(1):41–56

    Article  Google Scholar 

  28. Vahid B, Marik PE (2008) Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133(2):528–538

    Article  CAS  Google Scholar 

  29. Meadors M, Floyd J, Perry MC (2006) Pulmonary toxicity of chemotherapy. Semin Oncol 33(1):98–105

    Article  CAS  Google Scholar 

  30. Limper AH (2004) Chemotherapy-induced lung disease. Clin Chest Med 25(1):53–64

    Article  Google Scholar 

  31. Laforgia M et al (2021) Peripheral neuropathy under oncologic therapies: a literature review on pathogenetic mechanisms. Int J Mol Sci 22(4):1980–2002

    Google Scholar 

  32. Li Y, Lustberg MB, Hu S (2021) Emerging pharmacological and non-pharmacological therapeutics for prevention and treatment of chemotherapy-induced peripheral neuropathy. Cancers (Basel) 13(4):716–731

    Google Scholar 

  33. McQuade RM et al (2018) PARP inhibition in platinum-based chemotherapy: chemopotentiation and neuroprotection. Pharmacol Res 137:104–113

    Article  CAS  Google Scholar 

  34. Miltenburg NC, Boogerd W (2014) Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 40(7):872–882

    Article  CAS  Google Scholar 

  35. Hodgson KD et al (2013) A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 39(3):297–304

    Article  CAS  Google Scholar 

  36. Gutierrez-Gutierrez G et al (2010) Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 12(2):81–91

    Article  Google Scholar 

  37. Kahler KC et al (2016) Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges 14(7):662–681

    Google Scholar 

  38. Eggermont AMM, Kicinski M, Suciu S (2020) Management of immune-related adverse events affecting outcome in patients treated with checkpoint inhibitors-reply. JAMA Oncol 6(8):1301

    Article  Google Scholar 

  39. Hassel JC et al (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev 57:36–49

    Article  CAS  Google Scholar 

  40. Larkin J et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381(16):1535–1546

    Article  CAS  Google Scholar 

  41. Hodi FS et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480–1492

    Article  CAS  Google Scholar 

  42. Schadendorf D et al (2017) Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35(34):3807–3814

    Article  CAS  Google Scholar 

  43. Kähler KC et al (2020) Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update. J Dtsch Dermatol Ges 18(6):582–609

    Google Scholar 

  44. Weber J et al (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15(17):5591–5598

    Article  CAS  Google Scholar 

  45. Brahmer JR et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36(17):1714–1768

    Article  CAS  Google Scholar 

  46. Kähler KC et al (2016) Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom. J. der Deutschen Dermatologischen Gesellschaft 14:662–683

    Google Scholar 

  47. Teulings HE et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33(7):773–781

    Article  CAS  Google Scholar 

  48. Nishino M et al (2016) Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2(12):1607–1616

    Article  Google Scholar 

  49. de Filette J et al (2019) A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 51(3):145–156

    Article  Google Scholar 

  50. Stelmachowska-Banaś M, Czajka-Oraniec I (2020) Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr Connect 9(10):R207–r228

    Article  Google Scholar 

  51. Zhao C et al (2018) Anti-PD-L1 treatment induced central diabetes insipidus. J Clin Endocrinol Metab 103(2):365–369

    Article  Google Scholar 

  52. Piranavan P et al (2019) Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J Clin Endocrinol Metab 104(2):550–556

    Article  Google Scholar 

  53. Higham CE et al (2018) Society for endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 7(7):G1–g7

    Article  CAS  Google Scholar 

  54. Faje A et al (2019) Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol 181(3):211–219

    Article  CAS  Google Scholar 

  55. Borodic G, Hinkle DM, Cia Y (2011) Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg 27(4):e87–e88

    Article  Google Scholar 

  56. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7(10):2958–2970

    CAS  Google Scholar 

  57. Hassel JC, Al-Batran MKS, Hofheinz R-D (2010) Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie 33:94–98

    Article  CAS  Google Scholar 

  58. Boone SL et al (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72(3–4):152–159

    Article  CAS  Google Scholar 

  59. Nanney LB, King LE Jr, Dale BA (1990) Epidermal growth factor receptors in genetically induced hyperproliferative skin disorders. Pediatr Dermatol 7(4):256–265

    Article  CAS  Google Scholar 

  60. Agero AL et al (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55(4):657–670

    Article  Google Scholar 

  61. Hu JC et al (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56(2):317–326

    Article  Google Scholar 

  62. Bonner JA et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28

    Article  CAS  Google Scholar 

  63. Gutzmer R, Jager E, Vordermark D (2011) Adjuvant therapies in oncology: a critical benefit-risk assessment. Onkologie 34(Suppl 2):10–12

    Article  Google Scholar 

  64. Wollenberg A et al (2008) A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 17(9):790–792

    Article  Google Scholar 

  65. Lee JS et al (1995) Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. J Clin Oncol 13(6):1501–1508

    Article  CAS  Google Scholar 

  66. Robert C et al (2019) Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 381(7):626–636

    Article  CAS  Google Scholar 

  67. Larkin J et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867–1876

    Article  Google Scholar 

  68. Dummer R et al (2018) Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19(10):1315–1327

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Würzburg, Deutschland

    Manik Chatterjee

  2. Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Würzburg, Deutschland

    Anja Gesierich

  3. Medizinische Klinik und Poliklinik IV, LMU Klinikum, München, Deutschland

    Matthias Kroiß

  4. Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Deutschland

    Volker Kunzmann

Authors
  1. Manik Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anja Gesierich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Kroiß
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Volker Kunzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manik Chatterjee .

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie, Universitätsklinikum Würzburg, Würzburg, Deutschland

    Urs Müller-Richter

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chatterjee, M., Gesierich, A., Kroiß, M., Kunzmann, V. (2022). Nebenwirkungen und deren Management. In: Müller-Richter, U. (eds) Medikamentöse Tumortherapie von Kopf-Hals-Tumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62808-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62808-9_4

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62807-2

  • Online ISBN: 978-3-662-62808-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation